Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

EMBO Mol Med · 2016 · PMC5090659 · PMID 27742718

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Combined exposure of endothelial cells to VEGF‐A and ANG‐1 showed a trend to reduce ANG‐2 production induced by VEGF‐A (Fig 1 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.